Published in Mol Ther on June 06, 2016
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood (2017) 0.76
Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight (2017) 0.75
T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics (2017) 0.75
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Acute myeloid leukemia. N Engl J Med (1999) 7.04
Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol (1995) 5.75
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2014) 5.42
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol (2009) 2.00
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
Noninvasive bioluminescence imaging in small animals. ILAR J (2008) 1.59
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 1.58
Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol (2005) 1.42
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood (2013) 1.34
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia (2014) 1.32
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica (2001) 1.30
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther (2007) 1.25
T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther (2012) 1.21
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res (2014) 1.17
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther (2004) 1.13
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica (2009) 1.09
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia (2015) 1.09
New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother (2007) 1.06
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther (2014) 1.06
Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther (2014) 1.05
Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype. PLoS One (2012) 1.04
Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer (2006) 1.03
Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer (2010) 1.01
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther (2010) 1.00
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol (2014) 0.96
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med (2015) 0.95
Engineered T cells for cancer therapy. Cancer Immunol Immunother (2014) 0.95
IL-3 receptor expression, regulation and function in cells of the vasculature. Immunol Cell Biol (1996) 0.93
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Sci Rep (2016) 0.82
Antigen-specific T cell therapies for cancer. Hum Mol Genet (2015) 0.82
Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res (1987) 0.81
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica (2014) 0.80
Update on antigen-specific immunotherapy of acute myeloid leukemia. Curr Hematol Malig Rep (2015) 0.79
IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther (2005) 0.79
NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML. J Immunol Res (2015) 0.77